HK1199735A1 - Caninised tumour necrosis factor antibodies and methods of using the same - Google Patents
Caninised tumour necrosis factor antibodies and methods of using the sameInfo
- Publication number
- HK1199735A1 HK1199735A1 HK15100122.4A HK15100122A HK1199735A1 HK 1199735 A1 HK1199735 A1 HK 1199735A1 HK 15100122 A HK15100122 A HK 15100122A HK 1199735 A1 HK1199735 A1 HK 1199735A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- caninised
- methods
- same
- necrosis factor
- tumour necrosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161529020P | 2011-08-30 | 2011-08-30 | |
US201161531439P | 2011-09-06 | 2011-09-06 | |
PCT/GB2012/052115 WO2013030568A1 (en) | 2011-08-30 | 2012-08-29 | Caninised tumour necrosis factor antibodies and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1199735A1 true HK1199735A1 (en) | 2015-07-17 |
Family
ID=47755387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15100122.4A HK1199735A1 (en) | 2011-08-30 | 2015-01-07 | Caninised tumour necrosis factor antibodies and methods of using the same |
Country Status (10)
Country | Link |
---|---|
US (1) | US20140294815A1 (ko) |
EP (1) | EP2751139A1 (ko) |
JP (1) | JP2014526902A (ko) |
KR (1) | KR20140063752A (ko) |
CN (1) | CN103958545A (ko) |
AU (1) | AU2012300632A1 (ko) |
CA (1) | CA2847020A1 (ko) |
HK (1) | HK1199735A1 (ko) |
SG (1) | SG11201400222RA (ko) |
WO (1) | WO2013030568A1 (ko) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117603354A (zh) | 2013-12-20 | 2024-02-27 | 英特维特国际股份有限公司 | 具有经修饰的ch2-ch3序列的犬抗体 |
US10550194B2 (en) | 2014-09-30 | 2020-02-04 | Intervet Inc. | PD-L1 antibodies binding canine PD-L1 |
US11091556B2 (en) | 2015-12-18 | 2021-08-17 | Intervet Inc. | Caninized human antibodies to human IL-4R alpha |
CN107375950B (zh) * | 2017-08-02 | 2020-10-09 | 深圳大学 | 一种重组Gal-1过敏环境免疫耐受诱导模型及建立方法 |
WO2022133325A2 (en) * | 2020-12-18 | 2022-06-23 | Kindred Biosciences, Inc. | Tnf alpha and ngf antibodies for veterinary use |
TWI821881B (zh) * | 2021-01-29 | 2023-11-11 | 醫研生物科技有限公司 | 腫瘤壞死因子α重組抗體及其用途 |
CN117343185B (zh) * | 2023-12-06 | 2024-03-01 | 北京伟杰信生物科技有限公司 | 一种抗犬pd-1抗体及其用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
AU640397B2 (en) | 1989-08-25 | 1993-08-26 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin |
EP0590067A1 (en) | 1991-06-14 | 1994-04-06 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
EP2331579B1 (en) * | 2008-09-04 | 2017-07-05 | Vet Therapeutics, Inc. | Monoclonal antibodies |
-
2012
- 2012-08-29 WO PCT/GB2012/052115 patent/WO2013030568A1/en active Application Filing
- 2012-08-29 SG SG11201400222RA patent/SG11201400222RA/en unknown
- 2012-08-29 US US14/241,616 patent/US20140294815A1/en not_active Abandoned
- 2012-08-29 CN CN201280052125.8A patent/CN103958545A/zh active Pending
- 2012-08-29 KR KR1020147008446A patent/KR20140063752A/ko not_active Application Discontinuation
- 2012-08-29 AU AU2012300632A patent/AU2012300632A1/en not_active Abandoned
- 2012-08-29 CA CA2847020A patent/CA2847020A1/en not_active Abandoned
- 2012-08-29 JP JP2014527733A patent/JP2014526902A/ja active Pending
- 2012-08-29 EP EP12761783.5A patent/EP2751139A1/en not_active Withdrawn
-
2015
- 2015-01-07 HK HK15100122.4A patent/HK1199735A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
KR20140063752A (ko) | 2014-05-27 |
EP2751139A1 (en) | 2014-07-09 |
US20140294815A1 (en) | 2014-10-02 |
NZ621619A (en) | 2015-03-27 |
WO2013030568A1 (en) | 2013-03-07 |
CA2847020A1 (en) | 2013-03-07 |
SG11201400222RA (en) | 2014-03-28 |
CN103958545A (zh) | 2014-07-30 |
JP2014526902A (ja) | 2014-10-09 |
AU2012300632A1 (en) | 2014-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1255608A1 (zh) | 抗htra1抗體及使用方法 | |
IL250691A0 (en) | Anti-ox40 antibodies and methods of using them | |
HK1213581A1 (zh) | 抗- 抗體及其使用方法 | |
EP2748199A4 (en) | ANTI-OX40 ANTIBODIES AND METHOD FOR THEIR USE | |
ZA201308022B (en) | Anti-cd40 antibodies and methods of use | |
GB201114858D0 (en) | Anti-nerve growth factor antibodies and methods of using the same | |
FI3556774T3 (fi) | Anti-cd40-vasta-aineita ja niiden käyttötapoja | |
HK1201843A1 (en) | Anti-polyubiquitin antibodies and methods of use | |
ZA201403760B (en) | Anti-cd98 antibodies and methods of use thereof | |
GB201517547D0 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
EP2611832A4 (en) | ANTI-CXCL13 ANTIBODIES AND METHOD FOR THEIR USE | |
HK1199735A1 (en) | Caninised tumour necrosis factor antibodies and methods of using the same | |
HK1201541A1 (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
EP2682405A4 (en) | HUMANIZED ANTI-FACTOR ANTI-TUMOR NECROSIS FACTOR | |
GB201519606D0 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same |